아피메즈 파마슈티컬스 USAPUS 주가

Apimeds Pharmaceuticals Q1 EPS $(2.26) Down From $(0.50) YoY

Apimeds Pharmaceuticals (AMEX:APUS) reported quarterly losses of $(2.26) per share. This is a 352 percent decrease over losses of $(0.50) per share from the same period last year.

[10-Q] 분기 실적 — QUARTERLY REPORT

[NT 10-Q] 10-Q 제출 연기 — NOTIFICATION OF LATE FILING

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session

[SCHEDULE 13D/A] SCHEDULE 13D/A

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Veeco Instruments Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket

Veeco Instruments Inc (NASDAQ: VECO) rose in pre-market trading after reporting Q1 results and affirming FY26 sales guidance with midpoint above estimates. Other gainers include EZGO, EVC, GCTK, AVTX, OCG, COMP, ALIT, TBH, and SMCI, while losers include ATOM, NWGL, and APUS.

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

MATAWAN, N.J. & LA JOLLA, Calif., May 05, 2026--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the "Inscobee Parties"), resolving all outstanding disputes arising from the APUS’ December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company’s previously disclosed $100 million PIPE financing, and the advancement of L